Secukinumab is a human IgG1κ monoclonal antibody that functions by inhibiting interleukin-17A, making it a critical therapeutic agent for treating moderate to severe plaque psoriasis, ankylosing spondylitis,… Read more
Secukinumab is a human IgG1κ monoclonal antibody that functions by inhibiting interleukin-17A, making it a critical therapeutic agent for treating moderate to severe plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. The Secukinumab category provides essential materials for pharmaceutical research, including high-quality reference standards for the active pharmaceutical ingredient, as well as pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These specialized substances are vital for laboratories conducting rigorous impurity profiling, method validation, and ongoing quality control during drug development and manufacturing. By utilizing these precise analytical tools, researchers can ensure the safety and efficacy of final formulations through accurate identification and quantification of related substances. This collection supports comprehensive analytical testing protocols required to maintain compliance with regulatory standards for monoclonal antibody therapeutics.